Abstract
Introduction
A phase I study was performed to establish the minimum effective dose safety of the topical 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor lovastatin (FP252S) in preventing chemotherapy-induced alopecia in cohorts of three patients receiving their first doses of chemotherapy with doxorubicin (eight patients) or taxanes (four patients).
Results
One patient at the first dose level receiving doxorubicin and cyclophosphamide had only grade 1 hair loss at 3 weeks. At dose level 2, one patient on doxorubicin took more than 4 weeks to lose her hair and another on docetaxel retained some hair throughout her chemotherapy. At level 3, one patient had grade 2 hair loss at week 4 and another on docetaxel for 6 cycles showed evidence of hair growth between cycles. There were no grade 3 or 4 toxicities, but at the fourth dose level, no higher concentrations could be formulated.
Discussion
Lovastatin was well-tolerated at the maximum concentration achievable but showed little efficacy.
This is a preview of subscription content, log in via an institution to check access.
References
Benjamin B, Ziginskas D, Harman J, Meakin T (2002) Pulsed electrostatic fields (ETG) to reduce hair loss in women undergoing chemotherapy for breast carcinoma: a pilot study. Psychooncology 11:244–248
Crounse RG, Van Scott EJ (1960) Changes in scalp hair roots as a measure of toxicity from cancer chemotherapeutic drugs. J Invest Dermatol 35:83–90
Dean JC, Salmon SE, Griffiths KS (1997) Prevention of doxorubicin-induced hair loss with scalp hypothermia. N Engl J Med 301:1427–1429
DeSpain JD (1992) Dermatologic toxicity of chemotherapy. Semin Oncol 19:501–507
Fischer D, Knobf M, Durivage H (1997) The cancer chemotherapy handbook. Mosby, St. Louis, MO, pp 514–526
Duvic M, Lemak N, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, Trancik RJ, Bandstra BA, Compton LD (1996) A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 35:74–78
Hood AF (1996) Dermatologic toxicity. In: Perry MC (ed) The chemotherapy source book, 2nd edn. Williams & Wilkins, Baltimore, pp 595–606
Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z (1991) Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88:3628–3632
Keyomarsi K, Sandoval L, Band V, Pardee AB (1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51:3602–3609
Pillans PI, Woods DJ (1995) Drug-associated alopecia. Int J Dermatol 34:149–158
Ron IG, Kalmus Y, Kalmus Z, Inbar M, Chaitchik S (1997) Scalp cooling in the prevention of alopecia in patients receiving depilating chemotherapy. Support Care Cancer 5:136–138
Rodriguez R, Machiavelli M, Leone B, Romero A, Cuevas MA, Langhi M, Romero Acuna L, Romero Acuna J, Amato S, Barbieri M et al (1994) Minoxidil (Mx) as a prophylaxis of doxorubicin-induced alopecia. Ann Oncol 5(8):769–770
Macduff C, Mackenzie T, Hutcheon A, Melville L, Archibald H (2003) The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel. Eur J Cancer Care (Engl) 12(2):154–161
Grevelman EG, Breed WP (2005) Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 16(3):352–358
Ridderheim M, Bjurberg M, Gustavsson A (2003) Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer 11(6):371–377
Meijer L, Knockaert M, Damiens E (2001) Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors. Bull Cancer 88(4):347–350
Sredni B, Albeck M, Tichler T, Shani A, Shapira J, Bruderman I, Catane R, Kaufman B, Kalechman Y (1995) Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. J Clin Oncol 13(9):2342–2353
Wang J, Lu Z, Au JL (2006) Protection against chemotherapy-induced alopecia. Pharm Res 23(11):2505–2514
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Joshi, R., Olver, I., Keefe, D. et al. A phase I study to assess the safety and activity of topical lovastatin (FP252S) for the prevention of chemotherapy-induced alopecia. Support Care Cancer 15, 1109–1112 (2007). https://doi.org/10.1007/s00520-007-0267-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-007-0267-2